Press releaseACCESS Newswire
Ensysce Biosciences
ENSC · NASDAQ
$0.4986−$0.0043 (−0.86%)TodayMarket closed ·
Prev close $0.5029
Latest news
- Press releaseACCESS Newswire
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
- Press releaseACCESS Newswire
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
- Press releaseACCESS Newswire
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
- Press releaseACCESS Newswire
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
- Press releaseACCESS Newswire
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseACCESS Newswire
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Why Investors Are Watching These Healthcare Movers
- NewsAvi Kapoor
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
- News
Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseACCESS Newswire
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseGlobe Newswire
Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength
- NewsAvi Kapoor
Dow Dips Over 600 Points; US Producer Prices Increase In January
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Reiterates $18.45 Price Valuation; Was Originally Given On May 14, 2025
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $18.45 Price Valuation
- NewsAvi Kapoor
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.